Antibody Conjugate Oligonucleotides (ACOs) combine gene-modulating oligonucleotides with antibody-based cell targeting, offering a breakthrough in precision medicine. By selectively delivering therapies to diseased cells, ACOs reduce off-target effects and show promise in treating cancer, genetic, and neurological disorders. With rapid R&D and integration with tools like CRISPR, ACOs are shaping the future of personalized medicine.
For Sample Report, Click Here: https://tinyurl.com/4m7ha2...